Alpha Tau Medical has spent the past month staging an impressive rally — and its own CFO has been selling into every uptick.
The insider angle is the week's most telling signal. CFO Raphi Levy has executed at least ten separate sell transactions since late June, collectively totalling roughly $1.29 million in proceeds. The selling started at prices around $9.47, then continued at $10, $11, $12, and again above $13 and $14 — a systematic liquidation as the stock climbed 38% over the past month to close Thursday at $12.71. The pattern is notable: not a single insider purchase appears in the recent trade log against this backdrop of concentrated, ladder-up selling by the company's chief financial officer.
The borrow market tells a parallel story of growing caution. Availability has tightened sharply — dropping from a loose 97% last Tuesday to just 34% by Thursday, the tightest reading in weeks outside the early-June period. That rapid shift, nearly a 25% deterioration in one week, points to a sudden spike in demand for borrows. Short interest itself remains modest at roughly 2.4% of the free float, up about 4.6% on the week and 24% over the past month, so the tightening availability doesn't yet reflect a crowded short — it reflects new positioning building. Cost to borrow has actually eased over the same period, slipping to 8.4% from around 9.8%, suggesting the borrow demand has been absorbed without fully squeezing supply yet. Options traders, meanwhile, lean clearly bullish: the put/call ratio has fallen to 0.14, well below its 20-day average of 0.18 and running at a z-score of negative 1.6 — call volume thoroughly dominates. That divergence between options sentiment and tightening availability is the key tension in the setup.
The Street broadly agrees the stock has further to run, even if the targets are now in range of current prices. Barclays raised its target to $17 from $15 in early June while maintaining Overweight — the most aggressive call on the board. HC Wainwright holds at $15 with a Buy. The mean price target across covering analysts is $14.20, which is above current levels but not dramatically so after a 38% run. The bull case rests on Alpha DaRT's Phase 1/2 safety data — no treatment-related deaths, all Grade ≥3 adverse events resolved — and a cash runway extending through 2027. Bears point to limited near-term revenue, dependence on partnerships, and a pivotal pancreatic cancer pilot readout not expected until late 2026 or early 2027. Factor scores flag the tension: EPS surprise ranks at the 92nd percentile and 90-day EPS momentum at the 91st, but the short score rank sits at just the 16th percentile and availability rank at the 5th — the lending market is far tighter than the broader universe.
Institutional ownership concentration adds another layer of complexity. Oramed Pharmaceuticals holds 16% of shares, and founder Uzi Sofer holds nearly 13% — between them they control roughly 29% of the company. Neither reported any change at the last filing date. ARK Investment Management initiated a new position of 292,134 shares in Q1, and UBS Asset Management added 266,000 shares in the same period, both fresh entrants. That institutional buying against CFO selling creates an unusual cross-current: larger money is arriving as an insider with price-sensitive knowledge of the company's trajectory heads for the exit.
Earnings are scheduled for August 12, and the historical reaction pattern has been consistently positive on the day — the last four prints produced day-one moves of +9.5%, +3.1%, +4.2%, and +6.7% respectively, though the five-day drift has been more mixed. The next catalyst worth watching is therefore whether the pancreatic cancer pilot data timeline holds and whether Levy's selling pace continues as the stock approaches or tests the $14–$15 analyst target range.
See the live data behind this article on ORTEX.
Open DRTS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
